Is there a need for new phosphate binders to treat phosphate imbalance associated with chronic kidney disease?

Bibliography

• Berndt T, Kumar R. Phosphatonins and the regulation of phosphate homeostasis. Annu Rev Physiol 2007;69:341-59
   PubMed Web of Science ®Google Scholar
• Sabbagh Y, Giral H, Caldas Y, et al. Intestinal phosphate transport. Adv Chronic Kidney Dis 2011;18(2):85-90
   PubMed Web of Science ®Google Scholar
• Marks J, Debnam ES, Unwin RJ. Phosphate homeostasis and the renal-gastrointestinal axis. Am J Physiol Renal Physiol 2010;299(2):F285-96
   Google Scholar
• Bonjour JP. Calcium and phosphate: a duet of ions playing for bone health. J Am Coll Nutr 2012;30(5 Suppl 1):438S-48S
   Google Scholar
• National-Kidney-Foundation: chronic kidney disease (CKD). 2014. Available from: www.kidneyorg/kidneyDisease/ckd/indexcfm
   Google Scholar
• World-Kidney-Day: the cost of disease. 2014. Available from: www.worldkidneyday.org/
   Google Scholar
• Tonelli M, Wiebe N, Culleton B, et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 2006;17(7):2034-47
   PubMed Web of Science ®Google Scholar
• Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351(13):1296-305
   PubMed Web of Science ®Google Scholar
• Moe SM, Drueke TB, Block GA, et al. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009;113:S1-130
   PubMedGoogle Scholar
• Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15(8):2208-18
   PubMed Web of Science ®Google Scholar
• Kalantar-Zadeh K, Kuwae N, Regidor DL, et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006;70(4):771-80
   PubMed Web of Science ®Google Scholar
• Foley RN, Wang C, Collins AJ. Cardiovascular risk factor profiles and kidney function stage in the US general population: the NHANES III study. Mayo Clin Proc 2005;80(10):1270-7
   PubMed Web of Science ®Google Scholar
• Bellasi A, Mandreoli M, Baldrati L, et al. Chronic kidney disease progression and outcome according to serum phosphorus in mild-to-moderate kidney dysfunction. Clin J Am Soc Nephrol 2011;6(4):883-91
   PubMed Web of Science ®Google Scholar
• Eddington H, Hoefield R, Sinha S, et al. Serum phosphate and mortality in patients with chronic kidney disease. Clin J Am Soc Nephrol 2010;5(12):2251-7
   PubMed Web of Science ®Google Scholar
• National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42(4 Suppl 3):S1-201
   PubMed Web of Science ®Google Scholar
• Dhingra R, Sullivan LM, Fox CS, et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med 2007;167(9):879-85
   PubMed Web of Science ®Google Scholar
• Roman-Garcia P, Carrillo-Lopez N, Cannata-Andia JB. Pathogenesis of bone and mineral related disorders in chronic kidney disease: key role of hyperphosphatemia. J Ren Care 2009;35(Suppl 1):34-8
   PubMedGoogle Scholar
• Shioi A, Nishizawa Y. [Roles of hyperphosphatemia in vascular calcification]. Clin Calcium 2009;19(2):180-5
   PubMedGoogle Scholar
• Martin KJ, Gonzalez EA. Prevention and control of phosphate retention/hyperphosphatemia in CKD-MBD: what is normal, when to start, and how to treat? Clin J Am Soc Nephrol 2011;6(2):440-6
   PubMed Web of Science ®Google Scholar
• Iijima K. [Hyperphosphatemia and cardiovascular diseases: impact of vascular calcification and endothelial dysfunction]. Clin Calcium 2012;22(10):1505-13
   PubMedGoogle Scholar
• Wu-Wong JR, Noonan W, Ma J, et al. Role of phosphorus and vitamin D analogs in the pathogenesis of vascular calcification. J Pharmacol Exp Ther 2006;318(1):90-8
   PubMed Web of Science ®Google Scholar
• Bellorin-Font E, Ambrosoni P, Carlini RG, et al. Clinical practice guidelines for the prevention, diagnosis, evaluation and treatment of mineral and bone disorders in chronic kidney disease (CKD-MBD) in adults. Nefrologia 2013;33(Suppl 1):1-28
   PubMedGoogle Scholar
• Block GA, Ix JH, Ketteler M, et al. Phosphate homeostasis in CKD: report of a scientific symposium sponsored by the National Kidney Foundation. Am J Kidney Dis 2013;62(3):457-73
   PubMed Web of Science ®Google Scholar
• Seiler S, Reichart B, Roth D, et al. FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment. Nephrol Dial Transplant 2010;25(12):3983-9
   PubMed Web of Science ®Google Scholar
• Isakova T, Xie H, Yang W, et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011;305(23):2432-9
   PubMed Web of Science ®Google Scholar
• Kendrick J, Cheung AK, Kaufman JS, et al. FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol 2011;22(10):1913-22
   PubMed Web of Science ®Google Scholar
• Bergwitz C, Juppner H. Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. Annu Rev Med 2010;61:91-104
   PubMed Web of Science ®Google Scholar
• Kalantar-Zadeh K, Gutekunst L, Mehrotra R, et al. Understanding sources of dietary phosphorus in the treatment of patients with chronic kidney disease. Clin J Am Soc Nephrol 2010;5(3):519-30
   PubMed Web of Science ®Google Scholar
• Ritz E, Hahn K, Ketteler M, et al. Phosphate additives in food--a health risk. Dtsch Arztebl Int 2012;109(4):49-55
   PubMed Web of Science ®Google Scholar
• A registry and results database of publicly and privately supported clinical studies of human participants conducted around the world. 2014. Available from: http://clinicaltrials.gov
   Google Scholar
• Ketteler M, Biggar PH. Use of phosphate binders in chronic kidney disease. Curr Opin Nephrol Hypertens 2013;22(4):413-20
   PubMed Web of Science ®Google Scholar
• Jamal SA, Vandermeer B, Raggi P, et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet 2013;382(9900):1268-77
   PubMed Web of Science ®Google Scholar
• Cannata-Andia JB, Fernandez-Martin JL, Locatelli F, et al. Use of phosphate-binding agents is associated with a lower risk of mortality. Kidney Int 2013;84(5):998-1008
   PubMed Web of Science ®Google Scholar
• Block GA, Wheeler DC, Persky MS, et al. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol 2012;23(8):1407-15
   PubMed Web of Science ®Google Scholar
• Kakuta T, Tanaka R, Hyodo T, et al. Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients. Am J Kidney Dis 2011;57(3):422-31
   PubMed Web of Science ®Google Scholar
• Wada K, Wada Y. Evaluation of aortic calcification with lanthanum carbonate vs. calcium-based phosphate binders in maintenance hemodialysis patients with type 2 diabetes mellitus: an open-label randomized controlled trial. Ther Apher Dial 2014. [ Epub ahead of print]
   Web of Science ®Google Scholar
• De Santo NG, Frangiosa A, Anastasio P, et al. Sevelamer worsens metabolic acidosis in hemodialysis patients. J Nephrol 2006;19(Suppl 9):S108-14
   PubMed Web of Science ®Google Scholar
• Bellinghieri G, Santoro D, Savica V. Emerging drugs for hyperphosphatemia. Expert Opin Emerg Drugs 2007;12(3):355-65
   PubMed Web of Science ®Google Scholar
• Taniguchi K, Kakuta H, Tomura Y, Kaku S. Uchida W. [Pharmacological and clinical profile of bixalomer (Kiklin(R) capsules): a new therapeutic agent for hyperphosphatemia]. Nihon Yakurigaku Zasshi 2013;141(6):333-7
   PubMedGoogle Scholar
• Akizawa T, Kameoka C, Kaneko Y, Kawasaki S. Long-term treatment of hyperphosphatemia with bixalomer in Japanese hemodialysis patients. Ther Apher Dial 2014;17(6):612-19
   Web of Science ®Google Scholar
• Hatakeyama S, Murasawa H, Narita T, et al. Switching hemodialysis patients from sevelamer hydrochloride to bixalomer: a single-center, non-randomized analysis of efficacy and effects on gastrointestinal symptoms and metabolic acidosis. BMC Nephrol 2013;14:222
   PubMed Web of Science ®Google Scholar
• Savica V, Calo LA, Santoro D, et al. Salivary glands: a new player in phosphorus metabolism. J Ren Nutr 2011;21(1):39-42
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. 2014. Available from: www.fda.gov/food/guidanceregulation/guidancedocumentsregulatoryinformation/medicalfoods/default.htm
   Google Scholar
• Block GA, Persky MS, Shamblin BM, et al. Effect of salivary phosphate-binding chewing gum on serum phosphate in chronic kidney disease. Nephron Clin Pract 2013;123(1-2):93-101
   PubMed Web of Science ®Google Scholar
• Savica V, Calo LA, Monardo P, et al. Salivary phosphate-binding chewing gum reduces hyperphosphatemia in dialysis patients. J Am Soc Nephrol 2009;20(3):639-44
   PubMed Web of Science ®Google Scholar
• Kurihara S, Tsuruta Y, Akizawa T. Effect of MCI-196 (colestilan) as a phosphate binder on hyperphosphataemia in aemodialysis patients: a double-blind, placebo-controlled, short-term trial. Nephrol Dial Transplant 2005;20(2):424-30
   PubMed Web of Science ®Google Scholar
• Floege J, Covic AC, Ketteler M, et al. A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients. Kidney Int 2014. [ Epub ahead of print]
   Web of Science ®Google Scholar
• Wilkes BM, Reiner D, Kern M, Burke S. Simultaneous lowering of serum phosphate and LDL-cholesterol by sevelamer hydrochloride (RenaGel) in dialysis patients. Clin Nephrol 1998;50(6):381-6
   PubMed Web of Science ®Google Scholar
• Burke SK, Dillon MA, Hemken DE, et al. Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients. Adv Ren Replace Ther 2003;10(2):133-45
   PubMedGoogle Scholar
• Arenas MD, Rebollo P, Malek T, et al. A comparative study of 2 new phosphate binders (sevelamer and lanthanum carbonate) in routine clinical practice. J Nephrol 2010;23(6):683-92
   PubMed Web of Science ®Google Scholar
• Sprague SM. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate. Curr Med Res Opin 2007;23(12):3167-75
   PubMed Web of Science ®Google Scholar
• Hsu CH, Patel SR, Young EW. New phosphate binding agents: ferric compounds. J Am Soc Nephrol 1999;10(6):1274-80
   PubMed Web of Science ®Google Scholar
• McIntyre CW, Pai P, Warwick G, et al. Iron-magnesium hydroxycarbonate (fermagate): a novel non-calcium-containing phosphate binder for the treatment of hyperphosphatemia in chronic hemodialysis patients. Clin J Am Soc Nephrol 2009;4(2):401-9
   PubMed Web of Science ®Google Scholar
• Block GA, Brillhart SL, Persky MS, et al. Efficacy and safety of SBR759, a new iron-based phosphate binder. Kidney Int 2010;77(10):897-903
   PubMed Web of Science ®Google Scholar
• Chen JB, Chiang SS, Chen HC, et al. Efficacy and safety of SBR759, a novel calcium-free, iron(III)-based phosphate binder, in Asian patients undergoing hemodialysis: a 12-week, randomized, open-label, dose-titration study versus sevelamer hydrochloride. Nephrology (Carlton) 2011;16(8):743-50
   PubMed Web of Science ®Google Scholar
• Fukagawa M, Kasuga H, Joseph D, et al. Efficacy and safety of SBR759, a novel calcium-free, iron (III)-based phosphate binder, versus placebo in chronic kidney disease stage V Japanese patients on maintenance renal replacement therapy. Clin Exp Nephrol 2013;18(1):135-43
   PubMed Web of Science ®Google Scholar
• Baxter J, Shimizu F, Takiguchi Y, et al. Effect of iron(III) chitosan intake on the reduction of serum phosphorus in rats. J Pharm Pharmacol 2000;52(7):863-74
   PubMed Web of Science ®Google Scholar
• Burger C, Valcarenghi D, Sandri S, Rodrigues CA. Cross-linking chitosan-Fe(III), an oral phosphate binder: studies in vitro and in vivo. Int J Pharm 2001;223(1-2):29-33
   PubMed Web of Science ®Google Scholar
• Schoninger LM, Dall’Oglio RC, Sandri S, et al. Chitosan iron(III) reduces phosphorus levels in alloxan diabetes-induced rats with signs of renal failure development. Basic Clin Pharmacol Toxicol 2010;106(6):467-71
   PubMed Web of Science ®Google Scholar
• Spengler K, Follmann H, Boos KS, et al. Cross-linked iron dextran is an efficient oral phosphate binder in the rat. Nephrol Dial Transplant 1996;11(5):808-12
   PubMed Web of Science ®Google Scholar
• Hergesell O, Ritz E. Stabilized polynuclear iron hydroxide is an efficient oral phosphate binder in uraemic patients. Nephrol Dial Transplant 1999;14(4):863-7
   PubMed Web of Science ®Google Scholar
• Yamaguchi T, Baxter JG, Maebashi N, Asano T. Oral phosphate binders: phosphate binding capacity of iron (III) hydroxide complexes containing saccharides and their effect on the urinary excretion of calcium and phosphate in rats. Ren Fail 1999;21(5):453-68
   PubMed Web of Science ®Google Scholar
• Nakaki J, Yamaguchi S, Torii Y, et al. Effect of fatty acids on the phosphate binding of TRK-390, a novel, highly selective phosphate-binding polymer. Eur J Pharmacol 2013;714(1-3):312-17
   PubMed Web of Science ®Google Scholar
• Katai K, Tanaka H, Tatsumi S, et al. Nicotinamide inhibits sodium-dependent phosphate cotransport activity in rat small intestine. Nephrol Dial Transplant 1999;14(5):1195-201
   PubMed Web of Science ®Google Scholar
• Eto N, Miyata Y, Ohno H, Yamashita T. Nicotinamide prevents the development of hyperphosphataemia by suppressing intestinal sodium-dependent phosphate transporter in rats with adenine-induced renal failure. Nephrol Dial Transplant 2005;20(7):1378-84
   PubMed Web of Science ®Google Scholar
• Young DO, Cheng SC, Delmez JA, Coyne DW. The effect of oral niacinamide on plasma phosphorus levels in peritoneal dialysis patients. Perit Dial Int 2009;29(5):562-7
   PubMed Web of Science ®Google Scholar
• Cheng SC, Young DO, Huang Y, et al. A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients. Clin J Am Soc Nephrol 2008;3(4):1131-8
   PubMed Web of Science ®Google Scholar
• Koiwa F, Kazama JJ, Tokumoto A, et al. Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients. Ther Apher Dial 2005;9(4):336-9
   PubMed Web of Science ®Google Scholar
• Oliveira RB, Cancela AL, Graciolli FG, et al. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin J Am Soc Nephrol 2010;5(2):286-91
   PubMed Web of Science ®Google Scholar
• Gonzalez-Parra E, Gonzalez-Casaus ML, Galan A, et al. Lanthanum carbonate reduces FGF23 in chronic kidney disease Stage 3 patients. Nephrol Dial Transplant 2011;26(8):2567-71
   PubMed Web of Science ®Google Scholar
• Yilmaz MI, Sonmez A, Saglam M, et al. Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial. Am J Kidney Dis 2012;59(2):177-85
   PubMed Web of Science ®Google Scholar
• Fresenius Medical Care. 2014. Available from: www.fmcna.com/fmcna/index.htm
   Google Scholar
• Fresenius Medical Care Renal Pharmaceuticals, Europe. 2014. Available from: www.fmc-renalpharma.com/index.htm
   Google Scholar
• Pernix Therapeutics. 2014. Available from: www.eliphos.com
   Google Scholar
• Locatelli F, Dimkovic N, Spasovski G. Evaluation of colestilan in chronic kidney disease dialysis patients with hyperphosphataemia and dyslipidaemia: a randomized, placebo-controlled, multiple fixed-dose trial. Nephrol Dial Transplant 2013;28(7):1874-88
   PubMed Web of Science ®Google Scholar
• Locatelli F, Spasovski G, Dimkovic N, et al. The effects of colestilan versus placebo and sevelamer in patients with CKD 5D and hyperphosphataemia: a 1-year prospective randomized study. Nephrol Dial Transplant 2014;29(5):1061-73
   PubMed Web of Science ®Google Scholar
• Nephro-Tech, Inc. 2014. Available from: www.nephrotech.com
   Google Scholar
• Perrigo. 2014. Available from: www.perrigo.com
   Google Scholar
• Renagel package insert. 2014. Available from: www.renagel.com/default.asp
   Google Scholar
• Renvela. 2014. Available from: www.renvela.com/patients.aspx
   Google Scholar
• Shire. 2014. Available from: www.shire.com/shireplc/en/home
   Google Scholar
• Geisser P, Philipp E. PA21: a novel phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease. Clin Nephrol 2010;74(1):4-11
   PubMed Web of Science ®Google Scholar
• Wuthrich RP, Chonchol M, Covic A, et al. Randomized Clinical Trial of the Iron-Based Phosphate Binder PA21 in Hemodialysis Patients. Clin J Am Soc Nephrol 2013;8(2):280-9
   PubMed Web of Science ®Google Scholar
• Yokoyama K, Hirakata H, Akiba T, et al. Effect of oral JTT-751 (ferric citrate) on hyperphosphatemia in hemodialysis patients: results of a randomized, double-blind, placebo-controlled trial. Am J Nephrol 2012;36(5):478-87
   PubMed Web of Science ®Google Scholar
• Iida A, Kemmochi Y, Kakimoto K, et al. Ferric citrate hydrate, a new phosphate binder, prevents the complications of secondary hyperparathyroidism and vascular calcification. Am J Nephrol 2013;37(4):346-58
   PubMed Web of Science ®Google Scholar
• Sika M, Umanath K, Goral S, et al. Ferric citrate as a phosphate binder has a safety profile similar to sevelamer carbonate and calcium acetate. ASN Kidney Week Poster 2013;SA-PO540
   Google Scholar
• Weiner DE, Sika M, Dwyer JP, et al. Impact of ferric citrate, an oral phosphate binder, on mineral and bone metabolism markers in dialysis patients. Kidney Week Poster 2013;SA-PO543
   Google Scholar
• Yokoyama K, Hirakata H, Akiba T, et al. Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD. Clin J Am Soc Nephrol 2014;9(3):543-52
   PubMed Web of Science ®Google Scholar